NSCLC New TKI shows Effectiveness in EGFR-Resistance Mutation

被引：0
|
作者：
Manych, Matthias
机构：
来源：
PNEUMOLOGIE | 2015年 / 69卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：631 / 631
页数：1
相关论文
共 50 条
  • [41] Acquired resistance to EGFR-TKI in an uncommon G719S EGFR mutation
    Osoegawa, Atsushi
    Yamada, Tomonori
    Hashimoto, Takafumi
    Takumi, Yohei
    Kobayashi, Ryoji
    Suehiro, Shuji
    Miyawaki, Michiyo
    Takeuchi, Hideya
    Okamoto, Tatsuro
    Sugio, Kenji
    CANCER RESEARCH, 2017, 77
  • [42] In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC
    Xu-Dong Xiang
    Jing Yu
    Gao-Feng Li
    Lin Xie
    Heng Li
    Asian Pacific Journal of Tropical Medicine, 2014, (05) : 394 - 397
  • [43] EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis
    Liu, Sangtian
    Liang, Wenhua
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [45] In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC
    Xiang, Xu-Dong
    Yu, Jing
    Li, Gao-Feng
    Xie, Lin
    Li, Heng
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (05) : 394 - 397
  • [46] EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
    Zhu, Xuan
    Chen, Lijie
    Liu, Ling
    Niu, Xing
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [47] Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)
    Azuma, Koichi
    Takahama, Takayuki
    Sakai, Kazuko
    Takeda, Masayuki
    Hida, Toyoaki
    Hirabayashi, Masataka
    Oguri, Tetsuya
    Tanaka, Hiroshi
    Ebi, Noriyuki
    Sawa, Toshiyuki
    Bessho, Akihiro
    Tachihara, Motoko
    Akamatsu, Hiroaki
    Bandoh, Shuji
    Himeji, Daisuke
    Ohira, Tatsuo
    Shimokawa, Mototsugu
    Yamamoto, Nobuyuki
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S389 - S390
  • [48] Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis
    Feinberg, Bruce
    Halmos, Balazs
    Gucalp, Rasim
    Tang, Wenbo
    Moehring, Barbara
    Hochmair, Maximillian J.
    FUTURE ONCOLOGY, 2020, 16 (22) : 1585 - 1595
  • [49] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [50] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
12345